Improved 225AC daughter retention in InPO4 containing polymersomes

被引:26
|
作者
de Kruijff, R. M. [1 ]
Drost, K. [1 ]
Thijssen, L. [2 ]
Morgenstern, A. [3 ]
Bruchertseifer, F. [3 ]
Lathouwers, D. [1 ]
Wolterbeek, H. T. [1 ]
Denkova, A. G. [1 ]
机构
[1] Delft Univ Technol, Radiat Sci & Technol, Mekelweg 15, NL-2629 JB Delft, Netherlands
[2] SynerScope, Kastanjelaan 14, NL-5268 CA Helvoirt, Netherlands
[3] European Commiss, Joint Res Ctr, Directorate Nucl Safety & Secur, POB 2340, D-76125 Karlsruhe, Germany
关键词
ALPHA RADIONUCLIDE THERAPY; CALCIUM-PHOSPHATE; NANOPARTICLES; AC-225; ACTINIUM-225; LIPOSOMES; NUCLIDES; CARRIERS;
D O I
10.1016/j.apradiso.2017.07.030
中图分类号
O61 [无机化学];
学科分类号
070301 ; 081704 ;
摘要
Alpha-emitting radionuclides like actinium-225 (Ac-225) are ideal candidates for the treatment of small metastasised tumours, where the long half-life of (225)AC enables it to also reach less accessible tumours. The main challenge lies in retaining the recoiled alpha-emitting, daughter nuclides, which are decoupled from targeting agents upon emission of an alpha particle and can subsequently cause unwanted toxicity to healthy tissue. Polymersomes, vesicles composed of amphiphilic block copolymers, are capable of transporting (radio)pharmaceuticals to tumours, and are ideal candidates for the retention of these daughter nuclides. In this study, the Geant4 Monte Carlo simulation package was used to simulate ideal vesicle designs. Vesicles containing an InPO4 nanoparticle in the core were found to have the highest recoil retention, and were subsequently synthesized in the lab. The recoil retention of two of the daughter nuclides, namely francium-221 (Fr-221) and bismuth-213 (Bi-213) was determined at different vesicle sizes. Recoil retention was found to have improved significantly, from 37 +/- 4% and 22 +/- 1% to 57 +/- 5% and 40 +/- 2% for 221Fr and Bi-213 respectively for 100 nm polymersomes, as compared to earlier published results by Wang et al. where Ac-225 was encapsulated using a hydrophilic chelate (Wang et al. 2014). To better understand the different parameters influencing daughter retention, simulation data was expanded to include vesicle polydispersity and nanoparticle position within the polymersome. The high retention of the recoiling daughters and the (225)AC itself makes this vesicle design very suitable for future in vivo verification.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 27 条
  • [21] Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter
    Dayana Castillo Seoane
    Marijke De Saint-Hubert
    Stephen Ahenkorah
    Clarita Saldarriaga Vargas
    Maarten Ooms
    Lara Struelens
    Michel Koole
    EJNMMI Radiopharmacy and Chemistry, 7
  • [22] Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter
    Seoane, Dayana Castillo
    De Saint-Hubert, Marijke
    Ahenkorah, Stephen
    Vargas, Clarita Saldarriaga
    Ooms, Maarten
    Struelens, Lara
    Koole, Michel
    EJNMMI RADIOPHARMACY AND CHEMISTRY, 2022, 7 (01)
  • [23] 225Ac/89Zr labeled anti nectin 4 radioimmunoconjugates as theranostics against nectin 4 positive triple negative breast cancer
    Babeker, Hanan
    Njotu, Fabrice
    Ketchmen, Jessica
    Tikum, Florence
    Doroudi, Alireza
    Nwangele, Emmanuel
    Uppalapati, Maruti
    Fonge, Humphrey
    CANCER RESEARCH, 2024, 84 (06)
  • [24] Evaluation of 225Ac/134Ce-Macropa-PEG4-YS5 as a novel theranostic pair for prostate cancer therapy
    Bobba, Kondapa
    Bidkar, Anil
    Wadhwa, Anju
    Meher, Niranjan
    Drona, Suchi
    Bidlingmaier, Scott
    Chan, Emily
    Greenland, Nancy Y.
    VanBrocklin, Henry
    Liu, Bin
    Flavell, Robert
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [25] Rearmed Bifunctional Chelating Ligand for 225Ac/155Tb Precision-Guided Theranostic Radiopharmaceuticals-H4noneunpaX
    Wharton, Luke
    Yang, Hua
    Jaraquemada-Pelaez, Maria de Guadalupe
    Merkens, Helen
    Engudar, Gokce
    Ingham, Aidan
    Koniar, Helena
    Radchenko, Valery
    Kunz, Peter
    Schaffer, Paul
    Benard, Francois
    Orvig, Chris
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (19) : 13705 - 13730
  • [26] AKY-1189, a novel, first-in-class miniprotein radiopharmaceutical designed to deliver Actinium-225 (225Ac) to Nectin-4 expressing tumors with broad therapeutic applications in metastatic urothelial carcinoma (mUC) and other Nectin-4 expressing tumors
    Sathekge, M.
    Ndlovu, H.
    Kabunda, J.
    Mdlophane, A.
    Ramonaheng, K.
    Mdanda, S.
    Shungube, M.
    Mzizi, Y.
    Qebetu, M.
    Sebatana, R.
    Mokoala, K.
    Mashigoane, K.
    Zane, K.
    More, S.
    Vorster, M.
    Nasr, K.
    Morley, T.
    Kovacs, J.
    Horton, J.
    Herrmann, K.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S6 - S7
  • [27] Improved efficacy of α-emitters (225Ac, 213Bi) over β-emitter (90Y) labeled anti-HER-2/neu monoclonal antibody against early stage pulmonary metastasis
    Song, H.
    Esaias, C.
    Vajravelu, R.
    Hobbs, R. F.
    Apostolidis, C.
    Morgenstern, A.
    Sgouros, G.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2008, 23 (04) : 519 - 519